(A-C) Size exclusion chromatography/multi-angle light scattering (SEC-MALS) analysis of TRIP13 wildtype (A), N300A (B), and E253Q (C). Samples without added nucleotide are shown in black, with ATP-gS in green, and ATP (E253Q only) in blue. Thin lines indicate protein concentration (measured by change in refractive index, left axis), and thick lines indicate measured molecular weight (right axis). Best-fit TRIP13 oligomeric state for each peak, determined by measured molecular weights is shown above panel (A). For each construct, the measured and calculated molecular weights of each peak are shown in tables (right). For assembly of the TRIP13:p31 comet :MAD2 complex (Fig 1B,C) , TRIP13 E253Q was pre-incubated with ATP.
Appendix Figure S2 -TRIP13
E253Q :p31 comet :MAD2 XLMS and HDX-MS.
(A) Chemical crosslinking of TRIP13 E253Q :p31 comet :MAD2 with BS 3 at the indicated concentrations. Mass spectrometry was performed on all four crosslinked samples (see Fig 2 and Tables EV2, EV3 ). (B) Example mass spectra of the TRIP13 61-74 peptide (+2 charge state), in TRIP13 E253Q alone after 0, 1, 2, 5, and 10 minutes of H-D exchange. Early time-points show monoodal H-D exchange, while later timepoints show limited bimodal exchange. (C) Example mass spectra of a strongly bimodal peptide, TRIP13 residues 95-112 (+2 charge state), in TRIP13 E253Q alone after 0, 1, 2, 5, and 10 minutes of H-D exchange.
Appendix Figure S3 -MAD2/TRIP13 cysteine mutant validation and crosslinking. UV and conductivity traces from HiTrap Q HP purification of H. sapiens MAD2 S16A (blue) and S16K (yellow) mutants. For the experiments in Fig 7C, we pooled fractions containing O-MAD2 only. Similar analysis with C-MAD2 S16A fractions showed that this population is unstable, converting to O-MAD2 during subsequent gel-filtration and concentration steps, even though these steps were performed at 4°C (data not shown).
Material and Methods

Cloning and Protein Purification
Full-length human and mouse TRIP13, p31 comet , and MAD2 were amplified from cDNA clones and inserted into pET-based vectors with an N-terminal, TEV-protease cleavable His 6 tags, then variants were cloned using site-directed mutagenesis. For biochemical assays, full-length and N-terminally truncated mouse MAD2 constructs were cloned with an N-terminal His 6 -SUMO tag, which can be cleaved with the SUMO isopeptidase Ulp1 to leave no non-native residues at the N-terminus of the recombinant protein (Malakhov et al, 2004; Butt et al, 2005) . All MAD2 proteins used for biochemical assays contained the R133A mutant that compromised MAD2 homodimer formation (Sironi et al, 2001) , which allows purification of separate O-MAD2 and C-MAD2 populations via ion-exchange chromatography. We originally designed three MAD2 N-terminal deletions removing 5, 10, and 15 residues, but the MAD2-DN10 mutant was not cleavable by Ulp1, so it was not used in in vitro assays. The coding sequence for TRIP13 DCys (C14N, C93S, C264S, C341A; cysteines 189 and 334 were judged to be buried based on the TRIP13 crystal structure) was synthesized (GeneArt, Thermo-Fisher Scientific) and cloned as above, and MAD2 DCys (C79S, C106S, C149A) was cloned by PCR-based mutagenesis. Additional cysteines (TRIP13 W221C; MAD2 S6C, A17C, S25C, and S40C, along with re-introduced C79 and C106) were introduced into TRIP13 DCys and MAD2 DCys by PCR-based mutagenesis.
Proteins were expressed in E. coli strain Rosetta2(DE3)pLysS (EMD Millipore) except for human TRIP13, which was expressed in E. coli LOBSTR (Kerafast, Inc.) (Andersen et al, 2013) ; expression was induced with IPTG for 16-20 hours at 20°C. Proteins were purified by Ni 2+ -affinity (Ni-NTA; Qiagen) and ionexchange (Hitrap SP HP or Hitrap Q HP; GE Healthcare) chromatography, His 6 -tags were cleaved by incubation with TEV protease (Kapust et al, 2001 ) at 4°C overnight, and His 6 -SUMO tags were cleaved by incubation with S. cerevisiae Ulp1 at 4°C overnight. Uncleaved protein, cleaved tags, and proteases were removed by passing cleavage reactions over a Ni 2+ -affinity column a second time, and flow-through fractions were further purified by gel filtration (Superdex 200; GE Healthcare). For MAD2 R133A mutant proteins, O-MAD2 and C-MAD2 were separated on a HiTrap Q HP column (GE Healthcare), then separately purified thereafter and kept at 4°C to maintain conformation. Proteins were concentrated and stored at 4°C for crystallization, or at -80°C for biochemical assays.
Crystallization and Structure Determination
For crystallization, TRIP13
E253Q was concentrated to 15 mg/mL and exchanged into a buffer containing 25 mM Tris-HCl pH 7.5, 0.2 M NaCl, 5 mM MgCl 2 , and 1 mM TCEP. For crystallization without ATP, TRIP13 E253Q was mixed 1:1 in hanging drop format with well solution containing 0.1 M Tris-HCl pH 8.5, 0.8 M LiCl, and 4% PEG 3350. Crystals (~90 x 90 x 50 µM) were cryoprotected by addition of 20% glycerol and flash-frozen in liquid nitrogen. For ATP-bound TRIP13 E253Q , 1 mM ATP was added to the protein solution, then protein was mixed 1:1 in hanging drop format with well solution containing 0.1 M Tris-HCl pH 8.5, 0.2 M KCl, 10% pentaerythritol propoxylate. Crystals (~100 x 100 x 60 µm) were cryoprotected by addition of 10% glycerol and 12% pentaerythritol propoxylate (22% total) and flashfrozen in liquid nitrogen.
Our initial crystallization trials were performed with TRIP13 E253Q in complex with p31 comet and MAD2 (purified as in the next section), but these proteins are not detected in final electron density maps and are not essential for TRIP13 crystallization. We speculate that formation of the TRIP13 helical filament destroys a major element of the TRIP13-substrate interface (i.e. the top face of the TRIP13 hexamer), thereby destabilizing p31 comet :MAD2 binding. TRIP13 E253Q crystals used for final data collection were grown in the absence of p31 comet and MAD2.
X-ray diffraction datasets TRIP13 E253Q apo and TRIP13 E253Q ·ATP were collected on NE-CAT beamline 24ID-E at the Advanced Photon Source (Argonne National Laboratory, Argonne IL; see below for support statement). Crystals contained one monomer of TRIP13 per asymmetric unit. Data was processed by the in-house RAPD data-processing pipeline, incorporating XDS (Kabsch, 2010) for data reduction and AIMLESS (Evans & Murshudov, 2013) for scaling. Resolution cutoffs were determined using a CC 1/2 value (Pearson correlation coefficient of half-datasets) of ~0.5 (Karplus & Diederichs, 2012) . Phasing was performed by molecular replacement with PHASER (McCoy et al, 2007) , using a structure of C. elegans PCH-2 (PDB ID 4XGU) (Ye et al, 2015) with most side-chains removed. Initial models were iteratively rebuilt in COOT (Emsley et al, 2010) and refined using phenix.refine (Adams et al, 2010 ) with a consistent free-R set across multiple structures (Table EV1 ).
TRIP13
E253Q :p31 comet :MAD2 complex assembly and crosslinking mass spectrometry
For assembly of the TRIP13 E253Q :p31 comet :MAD2 complex, proteins were mixed in a final molar ratio of 2:1:1 (three copies of p31 comet :MAD2 per TRIP13 E253Q hexamer) in a buffer containing 20 mM HEPES pH 7.5, 0.3 M NaCl, 5 mM MgCl 2 , 5% glycerol and 1 mM ATP, then incubated for 60 minutes at 4°C. Complexes were injected onto a Superdex 200 Increase size exclusion column (GE Life Sciences) and fractions representing the TRIP13 E253Q hexamer plus associated p31 comet and MAD2 were pooled and concentrated to 1 mg/mL. Crosslinking was performed by addition of 0.2, 0.5, 1, or 2 mM isotopicallycoded D 0 /D 12 BS 3 (bis-sulfosuccinimidylsuberate; Creative Molecules) for 30 minutes at 30°C. The reaction was quenched by the addition of 100 mM NH 4 HCO 3 . Quenched reactions were supplemented with 8M urea to a final concentration of 6M. Subsequent to reduction and alkylation, crosslinked proteins were digested with Lys-C (1:50 w/w, Wako) for 3 h, diluted with 50 mM ammonium bicarbonate to 1M urea and digested with trypsin (1:50 w/w, Promega) overnight. Crosslinked peptides were purified by reversed phase chromatography using C18 cartridges (Sep-Pak, Waters). Crosslink fractions by peptide size exclusion chromatography and analyzed by tandem mass spectrometry (Orbitrap Elite, Thermo Scientific) (Herzog et al, 2012) . Fragment ion spectra were searched and crosslinks identified by the dedicated software program xQuest (Walzthoeni et al, 2015; Rinner et al, 2008) .
Hydrogen-Deuterium Exchange Mass Spectrometry
HD exchange experiments were conducted with a Waters Synapt G2S system. We examined six samples (all H. sapiens proteins): (1) MAD2 R133A in complex with a peptide encompassing residues 127-147 of CDC20 to maintain the C-MAD2 conformation; (2) p31 comet ; (3) TRIP13 E253Q :ATP; (4) MAD2 R133A :CDC20 127-147 + p31 comet (pre-mixed and purified by size exclusion chromatography) (5) TRIP13 E253Q :ATP + p31 comet (purified by size-exclusion chromatography); and (6) TRIP13 E253Q :ATP + MAD2 R133A :CDC20 127-147 +p31 comet (purified by size-exclusion chromatography). 5 uL samples containing 10 µM individual proteins or complexes in exchange buffer (300 mM NaCl, 20 mM Tris pH 7.5, 10% glycerol, 1 mM DTT) were mixed with 55 µL of the same buffer made with D 2 O for several deuteration times (0 sec, 1 min, 2 min, 5 min, 10 min) at 15°C. The exchange was quenched for 2 min at 1°C with an equal volume of quench buffer (3M guanidine HCl, 0.1% formic acid). A portion of the quenched sample (50 µL) was injected onto an online pepsin column (Applied Biosystems, Poroszyme Immobilized Pepsin cartridge). The resulting peptic peptides were then separated on a C18 column (Waters, Acquity UPLC BEH C18, 1.7 µm, 1.0 mm × 50 mm) fit with a Vanguard trap column using a 3-85% acetonitrile (containing 0.1% formic acid) gradient over 12 min at a flow rate of 40 µL/min. The separated peptides were directed into a Waters SYNAPT G2s quadrupole time-of-flight (qTOF) mass spectrometer. The mass spectrometer was set to collect data in the MSE, ESI+ mode; in a mass acquisition range of m/z 255.00−1950.00; with a scan time of 0.4 s. Continuous lock mass correction was accomplished with infusion of the LeuEnk peptide every 30 s (mass accuracy of 1 ppm for the calibration standard). The peptides were identified using PLGS version 2.5 (Waters, Inc.). The relative deuterium uptake for each peptide was calculated by comparing the centroids of the mass envelopes of the deuterated samples with the undeuterated controls using DynamX version 2.0 (Waters Corp.).
ATPase assays
ATPase reactions contained assay buffer (25 mM Tris-HCl at pH 7.5, 200 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 5% glycerol) plus 250 µM ATP, and were incubated 30 minutes at 37°C. Reactions were stopped and triplicate samples were assayed using the ADP-Glo kinase assay kit (Promega) in 384-well microplates using a TECAN (Mannedorf, Switzerland) Infinite M1000 spectrophotometer. Most assays were performed with 100 or 200 nM TRIP13 (monomer concentration); below this concentration ATPase activity was highly inconsistent, potentially due of dissociation of the TRIP13 hexamer. For most assays, p31 comet and MAD2 were added in excess, at 2 µM and 5 µM, respectively. Data were converted to K cat using a standard curve for ADP, and fit using PRISM version 7 (GraphPad Software, La Jolla CA).
Protein interaction assays
For MAD2-p31 comet binding assays, 10 µg His 6 -p31 comet was incubated with equimolar amounts of untagged MAD2 (FL or truncation mutants) in 50 µL binding buffer (20 mM HEPES pH 7.5, 200 mM NaCl, 5mM MgCl 2 , 5% glycerol, 20mM imidazole, 1mM 2-ME, 0.1% NP-40), incubated 60 minutes at 20°C, then 30 µL of a 50% slurry of Ni-NTA resin (Qiagen) was added and the mixture incubated with agitation for a further 30 minutes. Beads were then washed with 3 x 0.5 mL binding buffer, then eluted with 25 µL elution buffer. Input and Ni-NTA bound samples were analyzed by SDS-PAGE.
For fluorescence polarization assays, N-terminal FITC-labeled CDC20 closure motif peptide (residues 127-147; EAKILRLSGKPQNAPEGYQNR) was synthesized (Biomatik) and resuspended in binding buffer (25 mM Tris-HCl pH 7.5, 200 mM NaCl, 5% glycerol, 1 mM DTT, 0.1% NP-40). Fifty µL reactions containing 10 nM peptide plus 40 nM-40 µM MAD2 (FL or N-terminal truncations) were incubated 30 minutes at room temperature, then fluorescence polarization was read in 384-well plates using a TECAN Infinite M1000 PRO fluorescence plate reader. All binding curves were done in triplicate. Binding data were analyzed with Graphpad Prism v. 7 using a single-site binding model.
Cysteine crosslinking
Cysteine crosslinking assays were performed essentially as described (Yang et al, 2015) . Cysteine-activated MAD2 was prepared by: (1) incubating in crosslinking buffer (50 mM HEPES pH 7.5, 200 mM NaCl, 5 mM MgCl 2 , 5% glycerol) + 5 mM DTT for 60 minutes at 20°C; (2) buffer-exchange into DTT-free crosslinking buffer (Zeba-Spin desalting columns, Thermo Scientific) followed by addition of 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) to a concentration of 1 mM and incubation for 10 minutes at 20°C; (3) buffer-exchange into DTT-and DTNB-free crosslinking buffer. In this reaction, DTNB forms a mixed cysteine-TNB disulfide, with TNB forming an efficient leaving group that promotes disulfide formation in the presence of a second cysteine (Yang et al, 2015; Winther & Thorpe, 2014) . TRIP13
W221C and TRIP13
DCys were mixed in a 1:8 molar ratio in the presence of 1 mM ATP and 5 mM DTT in crosslinking buffer, incubated 60 minutes at 20°C, followed by buffer-exchange to DTT-free crosslinking buffer. p31 comet was prepared by incubation in crosslinking buffer + 5 mM DTT for 60 minutes at 20°C, followed by buffer-exchange to DTT-free crosslinking buffer. TRIP13 (20 µM monomers), MAD2 (5 µM), and p31 comet (5 µM) were mixed in the presence of 1 mM ATP or ATP-gS for 1 minute at 37°C in crosslinking buffer, then quenching buffer (200 mM iodoacetic acid (IAA), 400 mM Tris-HCl pH 8.5, 6.2 M urea, 2 mM EDTA) was added and samples were analyzed by non-reducing PAGE and Western blotting with anti-MAD2 (Bethyl #A300-301A, 1:5000 dilution) and anti-TRIP13 (Bethyl #A303-605A, 1:5000 dilution) antibodies. For the experiments in Fig 3C-D and Appendix Fig S3D, the membrane was blotted first for TRIP13, then stripped and blotted for MAD2.
Ion-exchange chromatography and MAD2 conversion assays
For examination of MAD2 conformation, ion-exchange chromatography was carried out largely as described (Ye et al, 2015) . Briefly, purified proteins or cell extracts (see below) were injected onto a 1 mL Mono-Q column (GE Health Sciences) in buffer containing 50 mM NaCl, then eluted with a gradient to 400 mM NaCl. Fractions were collected, analyzed by SDS-PAGE and visualized by Coomassie staining (purified proteins) or western blot (cell extracts).
For MAD2 conversion assays, 166 µL reactions with separately-purified M. musculus MAD2 R133A (fulllength or DN mutants), p31 comet , and TRIP13 were incubated at 20°C for two hours at 30 µM concentration (six-fold molar excess of p31 comet and MAD2 to TRIP13 hexamers), in ATPase assay buffer (pH 7.5) with 2 mM ATP. NaCl concentration was diluted to 50 mM, then reactions were analyzed by ionexchange chromatography as above.
Time-lapse imaging
For cell lines stably expressing siRNA-resistant MAD2 constructs, full-length or N-terminally truncated MAD2 was cloned from cDNA into pCDNA5/FRT/TO (Invitrogen) using a Gibson assembly kit (New England Biolabs). These were incorporated into parental Flp-In TRex-DLD-1 parental cells that stably express mRFP-tagged histone H2B (H2B-mRFP) (Han et al, 2013; Holland et al, 2010) using FRT/Flpmediated recombination (Tighe et al, 2004) . Expression of MAD2 variants were induced with with 1 µg/mL doxycycline. siRNAs directed against the 3′ untranslated region of Mad2 (5'-CCUAUUGAAUCAGUUUCCAAUUU-3'; 5'-CAGUAUAGGUAGGGAGAUAUU-3') or GAPDH (5'-UGGUUUACAUGAUCC-AAUA-3') were purchased from GE Dharmacon.
To determine unperturbed mitotic timing, cells were seeded onto CELLSTAR µClear 96-well plate (Greiner bio-one) with 50 nM of oligonucleotides using Lipofectamine RNAiMAX (Thermo Fisher). 24 hr after transfection, doxycline was added to express MAD2 for 24 hr before analyzing by time-lapse microscopy. Cells were maintained at 37°C and 5% CO 2 and images were collected using a CQ1 confocal image cytometer (Yokogawa) with a 40x objective at 10-min time intervals. Movies were assembled and analyzed using ImageJ (National Institutes of Health) software. To measure mitotic slippage, nocodazole was added 1hr before filming.
Mouse spermatocyte protein localization
To overexpress tagged proteins in spermatocytes, we injected 6-8 µl of an expression vector (5 µg/µl) under the control of a CMV promoter into the rete testis of live juvenile CD1 mice (13dpp) according to published protocol (Shibuya et al, 2014; Shoji et al, 2005) . One hour after injection, testes were held between tweezer type of electrodes (CUY650P5, Nepagene) and in vivo electroporation was carried out with four 50-ms pulses (35 Volts) with 950 ms intervals, then four equivalent pulses with opposite polarity (NEPA21 Electroporator, Nepagene). Spermatocytes were collected 24 h after electroporation for the detection of eGFP or 3xFLAG tagged genes in spermatocytes. All animals were used and maintained in accordance with the German Animal Welfare legislation ('Tierschutzgesetz'). All procedures pertaining to animal experiments were approved by the Governmental IACUC ('Landesdirektion Sachsen') and overseen by the animal ethics committee of the Technische Universität Dresden (license number DD24-5131/207/18).
Preparation of nuclear surface spreads of spermatocytes were carried out as described previously (Peters et al, 1997) . Briefly, testes tubuli were minced in a drop of PBS and resulting suspension was passed through 20 µm filter to remove clumps (Filcon, Cat No:340595) . Cell suspensions were diluted 1:2-1:5 with 100 mM sucrose, and 30 µl of diluted cell suspensions were added to microscopic slides covered with 100-120 µl of filtered (0.2 µm) 1% paraformaldehyde (PFA), 0.15% Triton X-100, 1 mM sodium borate pH 9.2 solution and incubated for 80 min at room temperature. Slides were dried at least 1 hour in a fume hood, then washed twice with 0.4% Photoflo (Kodak), once with water, then dried at room temperature. For immunostaining, slides were blocked with 2% BSA, 0.1 % Tween 20, 20 mM sodium azide in PBS for 30 minutes, and then incubated with primary antibodies for 3 hours at room temperature. Slides were then washed 3 x 5 minutes with PBS and incubated with secondary antibodies for 1 hour, then washed 3 x 5 minutes with PBS and mounted in Prolong Diamond AntiFade mountant (ThermoFisher). Primary antibodies used were monoclonal mouse anti-SYCP3 II52F10 (1:1, a gift from R. Jessberger), chicken anti-SYCP3 (1:300, homemade), rabbit anti-SYCP1 (1:1000, Abcam #15090), chicken anti-SYCP1 (1:300, homemade), rabbit anti-GFP (1:1000, ThermoFisher #A11122), monoclonal mouse ANTI-FLAG M2 (1:1000, Sigma-Aldrich #F1804). Goat secondary antibodies conjugated with Alexa Fluor 405 (ThermoFisher #A31553A31556, Abcam #175565), Alexa Fluor 488 (ThermoFisher #A11029/A11034), and Alexa Fluor 568 (ThermoFisher #A11031/11036) were used at 1:600 dilution. Images were acquired with Zeiss Axiophot fluorescence microscope and Axiocam MRm camera, using Axiovision software.
Advanced Photon Source support statement
Portions of this work were conducted at the Northeastern Collaborative Access Team beamlines at the Advanced Photon Source at Argonne National Laboratory, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). The Pilatus 6M detector on 24-ID-C beam line is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.
Data Availability
The crystal structures reported here are available at the Protein Data Bank (http://www.pdb.org) under the accession codes 5VQ9 (TRIP13 E253Q Apo; DOI 10.2210/pdb5vq9/pdb) and 5VQA (TRIP13 E253Q ·ATP; DOI 10.2210/pdb5vqa/pdb). Diffraction datasets for both structures are available at
